by Market Overview:
Plasmid DNA are self-replicating extrachromosomal double-stranded DNA molecules found in bacteria and some eukaryotic organisms like yeast and protozoa.They are used as DNA vectors in molecular cloning to propagate heterologous genes in self-replicating form. In the biopharmaceutical industry, plasmid DNA is used for genetic engineering and cell/gene therapy. It is widely used as therapeutic agents for treating diseases like cancer, and hemophilia. They are also used in vaccine manufacturing. Key applications of plasmid DNA include DNA vaccines and gene therapies for genetic disorders.
The Plasmid DNA manufacturing market is estimated to be valued at US$ 901.2 Bn or Mn in 2023 and is expected to exhibit a CAGR of 35% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The growing demand for therapeutic DNA vaccines and gene therapies is a major driver for the plasmid DNA manufacturing market. DNA vaccines are gaining prominence due to benefits like heat stability, ease of large-scale manufacture and lower costs compared to other vaccines. Emergence of new gene therapy applications for genetic disorders like cystic fibrosis, hemophilia is also fueling demand. Technological advancements in plasmid DNA manufacturing processes like large-scale plasmid production using fed-batch fermentation techniques and downstream plasmid purification are expected to reduce costs and improve yields. Growing outsourcing of plasmid DNA manufacturing to contract manufacturers by biopharma companies due to capital investment and expertise requirements is another factor propelling market growth. However, stringent regulations pertaining to quality and process validation pose a challenge for market players.
Segment Analysis
The global Plasmid DNA manufacturing market is dominated by the GMP grade plasmid DNA segment. GMP grade plasmids are essential for use in human clinical trials and therapies. They are manufactured and tested under cGMP conditions by qualified organizations. This segment accounts for over 60% of the overall market share due to growing demand for GMP grade plasmids from cell and gene therapy companies for human clinical research.
PEST Analysis
Political: Governments across major markets are providing funding and approvals to support cell and gene therapy research. For example, the US FDA has approved several gene and cell therapy products in the past few years.
Economic: The global Plasmid DNA manufacturing market is expected to grow at a CAGR of 35% during the forecast period due to increasing R&D investments by pharmaceutical and biotech companies in cell and gene therapies.
Social: Rising prevalence of cancer and other chronic diseases is driving demand for advanced treatment options like gene and cell therapies. This is increasing focus on plasmid DNA production.
Technological: Emerging technologies like continuous manufacturing systems and plasmid DNA purification methods are helping increase yields and lower production costs. This is supporting market growth.
Key Takeaways
The Global Plasmid DNA Manufacturing Market Size was valued at US$ 901.2 Bn in 2023 and is expected to reach over US$ 10 Bn by 2030. North America currently dominates the market due to presence of leading gene therapy companies and growing clinical research in the region.
Regional analysis: North America is expected to continue dominating the global Plasmid DNA manufacturing market during the forecast period. This can be attributed to increasing funding for cell and gene therapy research by governments and private organizations in the US. Additionally, the presence of major pharmaceutical companies and rapid approvals for gene therapies are supporting market growth in the region.
Key players: Key players operating in the Plasmid DNA manufacturing market include Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, and Waisman Biomanufacturing. Major players are focused on partnerships and capacity expansions to meet the growing demand for GMP grade plasmids.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
